NOVARTIS AG

NOVN
Delayed Quote. Delayed  - 04/15 11:31:49 am
80.53CHF +0.81%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (20.5%; Sandoz).
Net sales break down geographically as follows: Switzerland (1.7%), Germany (8.7%), France (5.1%), Europe (22.3%), the United States (34.3%), Americas (7.2%) and Asia/Africa/Australasia (20.7%).
On 9 April 2019, the group finalised the spin-off of Alcon.

Number of employees : 105 794 people.
Sales per Business
20192020
CHF
(in Million)
%CHF
(in Million)
%
Innovative Medicines 37,48079.4% 36,61880.2%
Sandoz 9,67120.5% 9,05419.8%
Sales per region
2020
CHF
(in Million)
%
United States 15,47233.9%
Europe 10,28322.5%
Asia/Africa/Australasia 4,54510%
Germany 4,2419.3%
Canada and Latin America 3,0426.7%
Japan 2,6325.8%
China 2,4155.3%
France 2,2925%
Switzerland 750.891.6%
Managers
Name Title
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Andreas von Planta Independent Non-Executive Director
Ann Marie Fudge Independent Non-Executive Director
Enrico Cipro Vanni Vice Chairman
Charles L. Sawyers Independent Non-Executive Director
William Thomas Winters Independent Non-Executive Director
Shareholders
Name Equities %
Novartis AG 210,238,872 8.52%
Sandoz Family Foundation 89,135,960 3.61%
The Vanguard Group, Inc. 57,327,726 2.32%
UBS Asset Management Switzerland AG 56,764,402 2.30%
Norges Bank Investment Management 56,446,398 2.29%
Novartis Foundation For Employee Participation 49,094,512 1.99%
Wellington Management Co. LLP 44,527,903 1.80%
Capital Research & Management Co. (Global Investors) 32,337,163 1.31%
Credit Suisse Asset Management (Schweiz) AG 31,469,445 1.28%
Zürcher Kantonalbank (Investment Management) 24,245,426 0.98%
Company contact information
Lichtstrasse 35
CH-4056 Basel, Basel-Stadt


Phone : +41 61 324 11 11
Fax : +41 61 324 80 01
web site : http://www.novartis.com
Markets and indexes
-
- Domestic Standard
- SMI / FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
Stock Exchange Codes
- Reuters Code :  NOVN.S
- Datastream Code :  S:NOVS
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
NOVARTIS AG-1.90%195 369
JOHNSON & JOHNSON1.61%421 022
ROCHE HOLDING AG-0.02%288 425
PFIZER INC.0.95%207 340
NOVARTIS AG-4.51%195 369
MERCK & CO., INC.-6.60%193 391
ABBVIE INC.-1.17%186 895
ELI LILLY AND COMPANY8.39%166 346
NOVO NORDISK A/S2.82%162 882
AMGEN INC.8.71%143 732
BRISTOL-MYERS SQUIBB COMPANY2.50%142 547
ASTRAZENECA PLC-0.72%131 672
SANOFI6.73%125 614
GLAXOSMITHKLINE PLC-3.90%88 637
JIANGSU HENGRUI MEDICINE CO., LTD.-26.27%69 532
CHUGAI PHARMACEUTICAL CO., LTD.-22.28%64 689
ALLERGAN PLC0.97%63 659
BAYER AG9.85%62 225
TAKEDA PHARMACEUTICAL COMPANY LIMITED-1.07%53 139
DAIICHI SANKYO COMPANY, LIMITED-14.71%52 365
ASTELLAS PHARMA INC.3.73%28 058
Brand Portfolio
A NOVARTIS COMPANY
A NOVARTIS COMPANY
ALCON
ALCON
AMBLYOTECH
AMBLYOTECH
ATAXION
ATAXION
AVEXIS
AVEXIS
CADENT THERAPEUTICS
CADENT THERAPEUTICS
CELLFORCURE
CELLFORCURE
ENDOCYTE
ENDOCYTE
IFM THERAPEUTICS
IFM THERAPEUTICS
IFM TRE
IFM TRE
NOVARTIS
NOVARTIS
SANDOZ CONSUMER PHARMACEUTICALS
SANDOZ CONSUMER PHARMACEUTICALS
SELEXYS
SELEXYS
THE MEDICINES COMPANY
THE MEDICINES COMPANY
» More brands of Novartis AG